Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18-F FAPI 74

Next Previous
Drug Profile

18-F FAPI 74

Alternative Names: [18F]FAPI-74

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Heidelberg
  • Developer SOFIE
  • Class Fluorine radioisotopes; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastrointestinal cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Jun 2025 GE Healthcare in collaboration with Leiden University Medical Center plans a phase II/III trial in Adenocarcinoma (Diagnosis) in Netherlands (IV) in June 2025 (NCT07018661)
  • 15 Jan 2025 18-F FAPI 74 is available for licensing as of 15 Jan 2025. www.sofie.com
  • 15 Jan 2025 SOFIE Biosciences plans clinical trials for Solid tumours (Diagnosis)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top